Abstract
Objective: Medical device acceptance of patients has grown considerably in recent years. This has question the effectiveness of the current regulatory frameworks to ensure the performance, safety, and quality of new devices. This article focuses on the methodical overview on hip and knee joint replacement medical devices evaluating the procedure and proper analysis of medical device regulation in three jurisdictions i.e. the United States of America (USA), EUROPE and INDIA, exploring reforms been laid to stabilize and meet the requirements of existing systems, and further analyse the additional actions which should be employed to fully meet this ultimate goal.
Methods: We analysed the hip and knee joint replacement medical device regulation system through a secondary research in United States, Europe and India in compliance with the updated national regulatory authority’s legislative documents and requirements.
Results: These three regulatory systems vary in their working, organization, acceptance for their specific pre- and post-market evidence requirements, and transparency of process. The most challenging factor remains the same for the countries which are to make sure safety and effectiveness of devices, proper monitoring of its use and important compliance information readiness employing quality management system towards new findings and acceptance for the users. A case study of Johnson & Johnson ASR Implant was also studied, highlighting the major reforms required and the reforms introduced in the United States, Europe and India. Thus, quality and safety reforms are made to strengthen the premarket compliance requirements, enhancing the need of post-market regulation through proper traceability and monitoring of devices by employing the functioning medical device registry.
Conclusion: Recent reforms address the major challenges in device regulation, highlighting the need to create connecting points between the device identifier system and existing data collection tools, such as electronic health records, and maintaining effective and up to date use of registries to ensure post-market use of new and existing devices.
Keywords: Medical device, knee joint replacement, hip joint replacement, THR, TKR, pharmacological.
Graphical Abstract
[1]
WHO. Medical Device – Full Definition. WHO. 2018
Available from: https://www.who.int/medical_devices/en/
[2]
Torosyan Y, Kurtz SM, Mihalko WM, Marinac-Dabic D, Rimnac CM. Editorial: Arthroplasty devices: Registries and beyond. Clin Orthop Relat Res 2015; 473(2): 403-5.
[http://dx.doi.org/10.1007/s11999-014-4061-4] [PMID: 25421957]
[http://dx.doi.org/10.1007/s11999-014-4061-4] [PMID: 25421957]
[3]
Malhotra R, Gautam D. Total hip arthroplasty in severe osteoporosis - technical tips to avert complications prophylactic locked plating along with total hip arthroplasty for severe osteoporosis with intramedullary Nail in Situ. J Osteoporos Phys Act 2017; 5: 1-4.
[http://dx.doi.org/10.4172/2329-9509.1000192]
[http://dx.doi.org/10.4172/2329-9509.1000192]
[4]
Bottai V, Dell’Osso G, Celli F, et al. Total hip replacement in osteoarthritis: The role of bone metabolism and its complications. Clin Cases Miner Bone Metab 2015; 12(3): 247-50.
[http://dx.doi.org/10.11138/ccmbm/2015.12.3.247] [PMID: 26811704]
[http://dx.doi.org/10.11138/ccmbm/2015.12.3.247] [PMID: 26811704]
[5]
Lee JK, Choi C-H. Total knee arthroplasty in rheumatoid arthritis. Knee Surg Relat Res 2012; 24(1): 1-6.
[http://dx.doi.org/10.5792/ksrr.2012.24.1.1] [PMID: 22570845]
[http://dx.doi.org/10.5792/ksrr.2012.24.1.1] [PMID: 22570845]
[6]
Bicanic G, Barbaric K, Bohacek I, Aljinovic A, Delimar D. Current concept in dysplastic hip arthroplasty: Techniques for acetabular and femoral reconstruction. World J Orthop 2014; 5(4): 412-24.
[http://dx.doi.org/10.5312/wjo.v5.i4.412] [PMID: 25232518]
[http://dx.doi.org/10.5312/wjo.v5.i4.412] [PMID: 25232518]
[7]
Morrissy RT. Atlas of pediatric orthopaedic surgery. 4th ed. New York: Lippincott Williams & Wilkins 1996; pp. 1-954.
[8]
Boileau P, Watkinson DJ, Hatzidakis AM, Balg F. Grammont reverse prosthesis: Design, rationale, and biomechanics. J Shoulder Elbow Surg 2005; 14(1)(Suppl. S): 147S-61S.
[http://dx.doi.org/10.1016/j.jse.2004.10.006] [PMID: 15726075]
[http://dx.doi.org/10.1016/j.jse.2004.10.006] [PMID: 15726075]
[9]
Brinker mark R Review of orthopaedic Trauma. 2nd ed. New York: Lippincott Williams and Wilkins 2013; pp. 1-607.
[10]
Abbas-Zadeh MR, Azizi A, Abbas-Zadeh L, Amirian F. Effect of surgical treatment on the quality of life in patients with non-traumatic avascular necrosis of the femoral head. Rev Bras Ortop 2018; 53(6): 773-7.
[http://dx.doi.org/10.1016/j.rboe.2017.08.021] [PMID: 30377614]
[http://dx.doi.org/10.1016/j.rboe.2017.08.021] [PMID: 30377614]
[11]
Moya-Angeler J, Gianakos AL, Villa JC, Ni A, Lane JM. Current concepts on osteonecrosis of the femoral head. World J Orthop 2015; 6(8): 590-601.
[http://dx.doi.org/10.5312/wjo.v6.i8.590] [PMID: 26396935]
[http://dx.doi.org/10.5312/wjo.v6.i8.590] [PMID: 26396935]
[12]
Ponzio DY, Pitta M, Carroll KM, Alexiades M. Hip arthroplasty for osteonecrosis of the femoral head secondary to alcohol abuse. Arthroplast Today 2018; 5(2): 172-5.
[http://dx.doi.org/10.1016/j.artd.2018.07.003] [PMID: 31286039]
[http://dx.doi.org/10.1016/j.artd.2018.07.003] [PMID: 31286039]
[13]
Dooley P, Secretan C. Total knee replacement: Understanding patient-related factors British Columbia Medical Journal. BCMJ 2016; 58(9): 514-9.
[14]
Schwartz FH, Lange J. Factors that affect outcome following total joint arthroplasty: A review of the recent literature. Curr Rev Musculoskelet Med 2017; 10(3): 346-55.
[http://dx.doi.org/10.1007/s12178-017-9421-8] [PMID: 28664450]
[http://dx.doi.org/10.1007/s12178-017-9421-8] [PMID: 28664450]
[15]
Anatone AJ, Shah RP, Jennings EL, Geller JA, Cooper HJ. A risk-stratification algorithm to reduce superficial surgical site complications in primary hip and knee arthroplasty. Arthroplast Today 2018; 4(4): 493-8.
[http://dx.doi.org/10.1016/j.artd.2018.09.004] [PMID: 30560182]
[http://dx.doi.org/10.1016/j.artd.2018.09.004] [PMID: 30560182]
[16]
Vaishya R, Patralekh MK, Bijukchhe AR, Vaish A, Vijay V, Agarwal AK. The top 10 arthroplasty articles published in last 10 years by Indian authors. J Clin Orthop Trauma 2018; 9(1): 94-100.
[http://dx.doi.org/10.1016/j.jcot.2017.09.006] [PMID: 29628690]
[http://dx.doi.org/10.1016/j.jcot.2017.09.006] [PMID: 29628690]
[17]
Singh JA. Epidemiology of knee and hip arthroplasty: A systematic review. Open Orthop J 2011; 5: 80-5.
[http://dx.doi.org/10.2174/1874325001105010080] [PMID: 21584277]
[http://dx.doi.org/10.2174/1874325001105010080] [PMID: 21584277]
[18]
Wengler A, Nimptsch U, Mansky T. Hip and knee replacement in Germany and the USA: Analysis of individual inpatient data from German and US hospitals for the years 2005 to 2011. Dtsch Arztebl Int 2014; 111(23-24): 407-16.
[http://dx.doi.org/10.3238/arztebl.2014.0407] [PMID: 24980673]
[http://dx.doi.org/10.3238/arztebl.2014.0407] [PMID: 24980673]
[19]
Argenson JN, Arndt M, Babis G, et al. Hip and knee section, treatment, debridement and retention of implant: Proceedings of international consensus on orthopedic infections. J Arthroplasty 2019; 34(2S): S399-419.
[http://dx.doi.org/10.1016/j.arth.2018.09.025] [PMID: 30348550]
[http://dx.doi.org/10.1016/j.arth.2018.09.025] [PMID: 30348550]
[20]
Hip Replacement — the engineer as a patient | quality
health care. Available from: https://qualityhealth-careplease.wordpress.com/2016/04/18/hip-replaceme-nt-the-engineer-as-a-patient/
[21]
Medacta Corporate | Hip replacement. Why total hip
replacement? Available from: https://www. medacta.com/EN/hip-replacement
[22]
France, Germany, Italy. European markets for trans
catheter embolization and occlusion devices. 2010.
Available from: https://www.marketsandmarkets. com/Market-Reports/occlusion-device-market-249840809.html?gclid=EAIaIQobChMIkLH_wcaJ5QIVw-FRCh0_7wL7EAAYASAAEgIcL_D_BwE
[23]
Medical devices. General information about hip implants.
Available from: https://www.fda.gov/Medical Devices/ProductsandMedicalProcedures/Implantsand Prosthetics/MetalonMetalHipImplants/ucm241594. htm
[24]
Medicaldevice standards and implant standards.
Available from: https://www.astm.org/Standards/medicaldevice-and-implant-standards.html
[26]
Wells JE, Clohisy JC, O’Keefe RJ. Treatment of intra-articular hip malignancy with extra-articular resection, preservation of the acetabular columns, and total hip arthroplasty. Arthroplast Today 2018; 4(4): 431-5.
[http://dx.doi.org/10.1016/j.artd.2018.07.007] [PMID: 30560171]
[http://dx.doi.org/10.1016/j.artd.2018.07.007] [PMID: 30560171]
[27]
Campi S, Tibrewal S, Cuthbert R, Tibrewal SB. Unicompartmental knee replacement - Current perspectives. J Clin Orthop Trauma 2018; 9(1): 17-23.
[http://dx.doi.org/10.1016/j.jcot.2017.11.013] [PMID: 29628678]
[http://dx.doi.org/10.1016/j.jcot.2017.11.013] [PMID: 29628678]
[28]
Understanding implants in knee and hip replacement.
Available from: https://www.hss.edu/condit-ions_understanding-implants-in-knee-and-hip-replacement.asp
[29]
Muir Emily. Evaluate MedTech: World Preview
2018. 2018. Available from: http://info.evaluate-group.com/rs/607-YGS-364/images/WPMT2018.pdf
[30]
Health C for D and R. International Medical Device
Regulators Forum (IMDRF). Available from: http://www.imdrf.org/
[31]
IMDRF management committee. (cited: 24 April
2019). Available from: http://www.imdrf.org/about/about.asp
[32]
CFR - Code of Federal Regulations Title 21-Food and
drugs. 2018. Available from: https://www.fda.gov/medical-devices/medical-device-databases/code-federal-regulations-title-21-food-and-drugs
[34]
Commissioner F. The Device Development Process -
Step 3: Pathway to Approval. 2018 Available from: https://www.fda.gov/patients/device-development-process/step-3-pathway-approval
[35]
Health C for D and R. Medical Device User Fee
Amendments (MDUFA) - MDUFA Guidance Documents.
2019. Available from: https://www.fda.gov/industry/medical-device-user-fee-amendments-mdufa/mdufa-guidance-documents
[36]
CDRCDRH. CFR - Code of Federal Regulations Title
21 - 800-1299. 2018. (cited: 22 March, 2018). Available
from: https://www.fda.gov/medical-devices/overview-device-regulation/code-federal-regulations-cfr
[37]
Boutrand J-P. EU Medical device regulatory framework:
Practical impact of new regulations. Int J of
oral scien 2013; 9(1): 1–8.
[38]
Van Drongelen A, Hessels J, Geertsma R. Comparison of market authorization systems of medical devices in USA and Europe 2015; 56
[39]
MDD revisions and new regulations. Available from: http://ec.europa.eu/health/medicaldevices/documents/revision/http://ec.europa.eu/health/medical-devices/documents/guidelines
[40]
Regulation (EU) 2017/745 – of the European Parliament
and of the Council on medical device amending
Directive 2001/83/EC, Regulation (EC) No 178/2002
and Regulation (EC) No 1223/2009 and repealing
Council Directives 90/385/EEC and 93/42/EEC. Off J
Eur Union L 2017; 117(1) Available at: https://eurlex.
europa.eu/legalcontent/
EN/TXT/PDF/?uri=CELEX:32017R0745
[41]
Regulation of the European Parliament. Regulation (EU) 2017/746 – of the European Parliament and of the Council on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU. Off J. Eur Union 2017; L177: 176-331.
[42]
The EU Medical Devices Regulation (MDR
2017/745). 2017. (cited: 5 April, 2017). Available
from: http://www.intertek.com/auditing/medical/mdr-2017-745/
[43]
Gatt C, Halliday S. A detailed review on the requirements of MDSAP participating countries in comparison with the European Medical Device Regulation 2017. Available from: https://www.bsigroup.com/meddev/LocalFiles/en-US/Whitepapers/bsi-md-whitepaper-vigilance.pdf
[44]
MoHFW (Department of Health and Family Welfare)
notification. Available from: http://www.mohfw. gov.bd
[45]
Kumar D, Yadav V, Mathewson N. A new regulatory paradigm for medical devices in India. Regul Focus 2017; pp. 1-15.
[46]
Rule MD. Central Drugs Standard Control Organization
(Medical Devices and Diagnostic Division )
Medical Devices ( MD ) Frequently Asked Questions
on Medical Device Rule , 2017 Doc No .: CDSCO /
FAQ / MD / 01 / 2018 2018: 1-15.
[47]
CDSCO. Medical Devices M Central Drug Standard
Control Organization (CDSCO). New Delhi: Applicant
User Manual for 2017. Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/SUGAM_user_manual.pdf
[48]
Sethi R, Popli H, Sethi S. Medical devices regulation
in United States of America, European Union and India:
A comparative study. Pharm Regul Aff Open
Access 2017; 06: 1-9.
[http://dx.doi.org/10.4172/2167-7689.10-00179]
[http://dx.doi.org/10.4172/2167-7689.10-00179]
[49]
Desai N. Analysis of Medical Devices Rules 2017.
Available at: http://www.nishithdesai.com/fileadmin/user_upload/pdfs/NDA%20Hotline/Analysis_of_Medical_Devices_Rules-2017.pdf
[50]
MOHFW GO. I. New drugs and clinical trials rules.
2019. (cited: 17 April, 2019).
Available from: https://cdsco.gov.in/opencms/open-cms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=NDI2MQ==
[51]
Sugam Online Portal - A Brief Overview Morulaa.
2019. (cited: 24 April, 2019). Available from: https://morulaa.com/cdsco/sugam-online-portal-a-brief-overview/
[52]
FDA Transition from QSR to ISO 13485: 2016.
(cited: 18 April, 2019). Available from: https://www. linkedin.com/pulse/fda-transition-from-21-cfr-820-qsr-iso-134852016-near-dallas-l-
[53]
CFR - Code of Federal Regulations Title 21 - 801
Labeling. 2019. (cited: 1 April, 2019). Available
from: https://www.accessdata.fda.gov/scripts/cdrh/cf docs/cfcfr/CFRSearch.cfm?CFRPart=801
[54]
Import Program – Food and Drug Administration
(FDA). 2019. Available from:https://www.fda.gov/industry/import-program-food-and-drug-administration-fda
[55]
Import Systems. 2017. (cited: 27 April, 2019). Available
from: https://www.fda.gov/industry/entry-process/import-systems
[56]
Entry Submission Process. 2019. (cited: 27 April,
2019). Available from: https://www.fda.gov/ind-ustry/entry-process/entry-submission-process
[57]
Medical Device Shelf-Life and Package Testing to
ISO 11607. 2019. (cited: 27 April, 2019). Available
from: https://www.emergobyul.com/services/worldwide/medical-device-shelf-life-and-package-testing-iso-11607
[58]
Imdrf. IMDRF/Registry WG/N42FINAL: 2017 Final
document. Methodological principles in the use of international
medical device registry data 2017. Available
from: http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-170316-methodological-principles.pdf
[59]
GHTF. GHTF/SG1/N063:2011 final document.
Global harmonization task force: Summary Technical
Documentation (STED) for demonstrating conformity
to the essential principles of safety and performance
of In Vitro Diagnostic Medical Devices. 2011. (cited:
17 March, 2011). Available from: http://www.imdrf.org/docs/ghtf/archived/sg1/technical-docs/ghtf-sg1-n063-2011-summary-technical-documentation-ivd-safety-conformity-110317.pdf
[60]
J&J’s subsidiary hip replacement row: A detailed
timeline of events that hit this global giant - The
Economic Times. 2019. (cited: 27 April, 2019).
Available from: https://economictimes.indiatimes. com/industry/healthcare/biotech/healthcare/jjs-subsidiary-hip-replacement-row-a-detailed-timeline-of-events-that-hit-this-global-giant/articleshow/65664114.cms.
[61]
Materiovigilance programme of india by akhilesh
sachan. 2019. (cited: 27 April, 2019). Available from: https://www.slideshare.net/AkhileshSachan/materiovigilance-programme-of-india-by-akhilesh-sachan
[62]
Jhaveri S. The medical device industry in India therapeutic areas KP bus consults LLP. 2016. Available
from: https://www.skpgroup.com/data/resource/skp_ the_medical_device_industry_in_india_therapeutic_ areas_.pdf
[63]
Rajbhandary S, Frank A. Trends to watch in the medical device industry in 2018. 2018. Available
from: https://mercercapital.com/assets/5-Trends-to-Watch-Med-Dev-Industry-2018.pdf
[64]
Rajbhandary S, Frank A. Business valuation & financial
advisory services: Orthopedics Overview. 2017.
Available from: https://mercercapital.com/assets/Ortho-Segment-2017.pdf
[65]
KPMG. Medical devices 2030 - Making a power play
to avoid the commodity trap. 2018. Available from: https://assets.kpmg/content/dam/kpmg/cn/pdf/en/201
8/04/medical-devices-2030.pdf
[66]
Wang J, Giuffrida A. The Development of Medical
Devices in Foreign Markets. Pharm Regul Aff
Open Access 2016; 5: 4-5.
[http://dx.doi.org/10.4172/2167-7689.1000167]
[http://dx.doi.org/10.4172/2167-7689.1000167]
[67]
Welch J, Babitt J, Llp Y. When the human body is the biggest data platform, how will medtech companies capture value? 2018. Available from: https://www.ey.com/Publication/vwLUAssets/ey-pulse-of-the-industry-2018/$FILE/ey-pulse-of-the-industry-2018.pdf
[68]
Deloitte. NAT HEALTH. Medical Devices: Making
in India - A Leap for Indian Healthcare. 2016.
Available from: https://www2.deloitte.com/content/dam/Deloitte/in/Documents/life-sciences-health-care/in-lshc-medical-devices-making-in-india-noexp.pdf
[69]
Preparing for the future: The new European Union
medical devices regulation. 2016. Available from: https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/gx-eu-med-device-regulation.pdf
Article Metrics
18
3